– Preliminary revenues between $99.0 million and $99.5 million for 2016, a year-over-year increase of 150 percent;
– 244,000 Cologuard tests completed in 2016, a year-over-year increase of 134 percent;
– 9,500 additional providers ordered Cologuard during the fourth quarter, and insurance coverage expanded by 67 percent during 2016.
Exact Sciences Corp. (Nasdaq: EXAS) announced today that the company expects to report revenues between $34.9 million and $35.4 million for the fourth quarter ended Dec. 31, 2016, an increase of 142 percent from the same quarter of 2015. The company completed approximately 82,000 Cologuard tests during the fourth quarter of 2016, which represents growth of 114 percent from the same period of 2015.
For the full-year 2016, the company anticipates revenues between $99.0 million and $99.5 million, a year-over-year increase of 150 percent. Completed Cologuard test volume during 2016 was approximately 244,000 tests, a 134-percent increase from 2015.
More than 9,500 health care providers ordered Cologuard for the first time during the fourth quarter ended Dec. 31, 2016. The number of providers who have ordered Cologuard since it was launched increased to nearly 60,000 during 2016, an increase of 122 percent from the prior year. Read the full release here.